Popular weight-loss drugs may prevent life-threatening cardiac complications following heart attacks. Research indicates these GLP-1 medications open microscopic blood vessels that often remain blocked post-event.
The discovery by University of Bristol and University College London researchers explains how GLP-1 drugs, which mimic a hormone regulating blood sugar and appetite, protect heart tissue from the "no-reflow" condition. This complication occurs when tiny blood vessels in the heart muscle remain narrowed even after emergency treatment, restricting blood flow and increasing the risk of heart failure and death.
When administered, GLP-1 signals the brain, which then signals the heart to activate potassium channels in pericyte cells. This action relaxes the pericytes, widening small blood vessels and improving blood flow to the heart muscle. The findings suggest existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments to reduce tissue damage during or immediately after a heart attack. Further clinical trials are needed to confirm efficacy in humans.